Controlling of genotoxic impurities in pharmaceuticals: International harmonisation of regulatory requirements

被引：0
|
作者：
Kasper, P. [1 ]
机构：
[1] BfArM Bundesinst Arzneimittel & Med Prod, Bonn, Germany
来源：
TOXICOLOGY LETTERS | 2011年 / 205卷
关键词：
D O I：
10.1016/j.toxlet.2011.05.031
中图分类号：
R99 [毒物学（毒理学）];
学科分类号：
100405 ;
摘要：
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [21] Recent advances in analysis of hazardous genotoxic impurities in pharmaceuticals by HPLC, GC, and CE
    Al Azzam, Khaldun M.
    Aboul-Enein, Hassan Y.
    [J]. JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2016, 39 (01) : 1 - 7
  • [22] Evaluation of the carcinogenic potential of pharmaceuticals - Opportunities arising from the International Conference on Harmonisation
    Monro, AM
    MacDonald, JS
    [J]. DRUG SAFETY, 1998, 18 (05) : 309 - 319
  • [23] Proposal for Class-Specific TTC Values of Potentially Genotoxic Impurities (PGI) in Pharmaceuticals
    Zeller, A.
    Brigo, A.
    Struwe, M.
    Singer, T.
    Gocke, E.
    [J]. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2011, 52 : S76 - S76
  • [24] Requirements for water for pharmaceutical purpose in the USA and Europe - State of international harmonisation
    Haberer, K
    [J]. PHARMAZEUTISCHE INDUSTRIE, 2000, 62 (06): : 459 - 463
  • [25] Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches
    Bhirud, Darshan
    Agrawal, Gyan
    Shah, Harshil
    Patel, Artiben
    Palkar, Mahesh B.
    Bhattacharya, Sankha
    Prajapati, Bhupendra G.
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2024, 24 (06) : 503 - 522
  • [26] Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals
    Horne, Stephen
    Nagavelli, Laxma R.
    Sayeed, Vilayat A.
    Heckman, Laurel
    Johnson, Deborah
    Berger, Dan
    Yip, Yean Yean
    Krahn, Carolina Lopes
    Sizukusa, Leticia Oyamada
    Rocha, Nayrton Flavio Moura
    Ludwig, Joachim
    Keire, David A.
    Condran, Gary
    Vera, Matthew D.
    Bream, Robert N.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 112 (05) : 1166 - 1182
  • [27] Intertwining Regmes: Trade, Intellectual Property and Regulatory Requirements for Pharmaceuticals
    Timmemans, Karin
    [J]. JOURNAL OF WORLD INTELLECTUAL PROPERTY, 2005, 8 (01): : 67 - 74
  • [28] Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: A comprehensive review
    Reddy, Ambavaram Vijaya Bhaskar
    Jaafar, Jafariah
    Umar, Khalid
    Majid, Zaiton Abdul
    Bin Aris, Azmi
    Talib, Juhaizah
    Madhavi, Gajulapalle
    [J]. JOURNAL OF SEPARATION SCIENCE, 2015, 38 (05) : 764 - 779
  • [29] A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity
    Müller, L
    Mauthe, RJ
    Riley, CM
    Andino, MM
    De Antonis, D
    Beels, C
    DeGeorge, J
    De Knaep, AGM
    Ellison, D
    Fagerland, JA
    Frank, R
    Fritschel, B
    Galloway, S
    Harpur, E
    Humfrey, CDN
    Jacks, AS
    Jagota, N
    Mackinnon, J
    Mohan, G
    Ness, DK
    O'Donovan, MR
    Smith, MD
    Vudathala, G
    Yotti, L
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 44 (03) : 198 - 211
  • [30] Assessment and Acceptance of Thresholds of Genotoxic Impurities in New Drug SubstancesA Regulatory Perspective
    Peter Kasper
    [J]. International Journal of Pharmaceutical Medicine, 2004, 18 (4) : 209 - 214
12345